(3.238.130.97) 您好!臺灣時間:2021/05/18 11:09
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

: 
twitterline
研究生:蔡達慶
研究生(外文):Da-Cing Cai
論文名稱:苦瓜萃取物對STZ誘發之糖尿病鼠慢性發炎及凝血機制影響之探討
論文名稱(外文):Effect of Momordica charantia L. (bitter gourd) extract on chronic inflammation and blood coagulation in STZ-induced diabetic rats
指導教授:詹恭巨詹恭巨引用關係
指導教授(外文):Kung-Chi Chan
學位類別:碩士
校院名稱:靜宜大學
系所名稱:食品營養研究所
學門:醫藥衛生學門
學類:營養學類
論文種類:學術論文
論文出版年:2007/08/
畢業學年度:96
語文別:中文
論文頁數:93
中文關鍵詞:抗凝血&抗凝血&抗凝血&抗凝血&抗凝血&抗凝血&抗凝血&抗凝血&
外文關鍵詞:malondialdehydeC-reactive proteininterleukin-6von Willebrand factorcoagulation factor VIIMomordica charantia extract
相關次數:
  • 被引用被引用:2
  • 點閱點閱:849
  • 評分評分:
  • 下載下載:258
  • 收藏至我的研究室書目清單書目收藏:0
高血糖所誘發之血管慢性發炎和凝血機制異常,是造成糖尿病患併發心血管疾病的主要原因。文獻指出,苦瓜具有降血糖及降血脂之功效,但是否能改善血栓性併發症之危險性仍然未知。因此本研究是以注射Streptozotocin (STZ,45mg/kg B.W.)誘發之糖尿病大鼠為模式,探討給予苦瓜萃取物對於慢性發炎及凝血機制之影響。實驗分為對照組及實驗組,實驗組又分為糖尿病(DM)組及給予苦瓜萃取物(200mg/kg B.W.) DM組,實驗為期八週後進行犧牲,並分析各組間之血糖、脂質過氧化、慢性發炎之狀態、血管內皮細胞之損傷、凝血及抗凝血活性之變化。結果顯示,給予八週苦瓜萃取物能顯著降低糖尿病鼠之禁食血糖值、脂質過氧化物-丙二醛(MDA)、發炎性指標-C反應蛋白(CRP)、發炎性細胞激素-介白素-6(IL-6)之濃度( p < 0.05 ),並有降低von Willebrand factor (vWF)濃度及凝血因子VII活性之趨勢,但對於抗凝血酶III活性則無影響。綜合上述結果得知,給予糖尿病鼠200mg/kg BW之苦瓜萃取物能有效降低高血糖所誘發之氧化壓力,並且改善體內之發炎現象,進而減少罹患心血管疾病之危險性。
Hyperglycemia-induced chronic inflammation and abnormal blood coagulation may play an important role in the development of cardiovascular diseases in type 2 diabetic patients. The hypoglycemic and hypolipidemic effect of Momordica charantia L. (MC) is well-known; however, it is not clear whether MC may lower the risk of diabetic complications. Therefore, the purpose of this study was to investigate the effect of MC extract on chronic inflammation and blood coagulation in STZ-induced diabetic rats. Twenty-four male Wistar rats were randomly assigned into three experimental groups, including normal control, diabetic control (DC), and diabetic with MC extract (200mg/kg B.W.) group (DMC). After 8 weeks of feeding, plasma concentration of fasting glucose, malondialdehyde (MDA), inflammatory marker (C-reactive protein, CRP), interleukin-6 (IL-6), von Willebrand factor (vWF), activity of coagulation factor VII and anticoagulation factor (antithrombin III, AT-III) were measured. The results of this study showed that plasma concentration of fasting glucose, MDA, CRP, IL-6 was decreased significantly (p&lt;0.05) by feeding MC extract to diabetic rats. Plasma concentration of vWF and activity of factor VII tended to be decreased in DMC group. AT-III activity was not affected by MC intake. In conclusion, MC extract at 200mg/kg BW may have beneficial effects to decrease oxidative stress, to ameliorate chronic inflammation, and hence decrease the risk to develop thrombogenic complications in diabetic rats.
目錄……………………………………………………… ….......I
圖目錄…………………………………………………… ……..….IV
表目錄…………………………………………………… ………...V
中文摘要……………………………………………………………..VI
英文摘要……………………………………………………………..VII

第一章 前言……………………………………………………...1

第二章 文獻回顧………………………………………………...3
第一節 糖尿病之介紹…………………………………………...3
第二節 糖尿病之慢性併發症…………………………………...7
第三節 糖尿病與氧化壓力……………………………… …….17
第四節 糖尿病與慢性發炎反應…………………………… ….18
第五節 糖尿病與凝血因子…………………………… ……….21
第六節 苦瓜之簡介…………………………………… ….....26
第七節 研究目的…………………………………………… ….30

第三章 材料與方法……… ……………………………….....31
第一節 材料………………...………………………………….31
第二節 體外試驗………………………… …………………….33
第三節 活體試驗……………………………… ……………….35
一、 動物實驗及實驗設計………………………… ….....35
二、 試驗分析方法…………………………………… …….37
(一) 非管制性麻藥的配置…………………………… …...37
(二) 禁食血糖值之測定……………………… …….......37
(三) 血漿丙二醛含量之測定..........................38
(四) 血漿C-反應蛋白含量之測定......................38
(五) 血漿介白素-6含量之測定……………………........39
(六) 血漿von Willebrand Factor含量之測定 ……......40
(七) 血漿凝血因子VII活性之測定……………… ........40
(八) 血漿第三抗凝血酶活性之測定……………… .......41
第四節 統計方法…………………………………… …….....42

第四章 結果………………………… …………………..…...43
第一節 體外試驗……………………… ………………….....43
第二節 活體試驗………………… ……………………….....43
一、 苦瓜萃取物對STZ誘發之糖尿病大鼠體重、每日攝食
和飲水之影響…………………… …………………43
二、 苦瓜萃取物對STZ誘發之糖尿病大鼠各相對器官重量
之影響……………………………………………………44
三、 苦瓜萃取物對STZ誘發之糖尿病大鼠禁食血糖之影響 44
四、 苦瓜萃取物對STZ誘發之糖尿病大鼠血漿MDA濃度
之影響………………………… ………………………44
五、 苦瓜萃取物對STZ誘發之糖尿病大鼠血漿C-反應蛋白
(CRP)和介白素-6 (IL-6)濃度之影響……………....45
六、 苦瓜萃取物對STZ誘發之糖尿病大鼠血漿von
Willebrand factor(vWF) 濃度之影響…… ……...45
七、 苦瓜萃取物對STZ誘發之糖尿病大鼠血漿凝血因子
VII (FVII)與第三抗凝血酶 (AT-III) 活性之影響..45

第五章 討論…………………………… ……………………….57
第一節 體外試驗……………………………… ……………….57
第二節 苦瓜萃取物對STZ誘發之糖尿病大鼠體重、每日攝
食和飲水、相對器官重量之引響…… ……………...58
第三節 苦瓜萃取物對STZ誘發之糖尿病大鼠禁食血糖之影響.60
第四節 苦瓜萃取物對STZ誘發之糖尿病大鼠血漿MDA濃度之
影響……………………………………… …………….60
第五節 苦瓜萃取物對STZ誘發之糖尿病大鼠血漿CRP、
IL-6濃度之影響…………………… ………………….61
第六節 苦瓜萃取物對STZ誘發之糖尿病大鼠血漿von
Willebrand factor (vWF) 濃度之影響……………..63
第七節 苦瓜萃取物對STZ誘發之糖尿病大鼠血漿凝血因子VII
(FVII)活性之影響………………………… ………...65
第八節 苦瓜萃取物對STZ誘發之糖尿病大鼠第三抗凝血酶
(AT-III)活性之影響………………………… ……….67

第六章 結論…………………… ……………………………….68


第七章 參考文獻……… ……………………………………….69
何敏夫 (2002) 血液學。合記圖書出版社,台北市

齊文隆 (2005) 苦瓜栽培管理。台中農業區栽培管理,http://www.tdais.gov.
tw/.../農業專業訓練/蔬菜栽培/農業專業訓練講義-2/苦瓜栽培管理.htm

全中和 (2006) 苦瓜新品種花蓮2號簡介。行政院農委會農政與農情170期,http://www.coa.gov.tw/view.php?catid=11529

林天送 (1995) 氫基自由基: 毒性極高的破壞分子。健康世界 112: 6-10.

陳淑娟 (2000) 臨床營養學。合記圖書出版社,台北市。

Abe, K. (1993) A study on the participation of protein kinase C in the blood coagulation. Hokkaido. Igaku. Zasshi. 68: 368-376.

Abou-Seif, M. A. & Youssef, A. A. (2004) Evaluation of some biochemical changes in diabetic patients. Clin. Chim. Acta. 346: 161-170.

ADA. (2007) Diagnosis and classification of diabetes mellitus. Diabetes Care 30: 42-47.

Ahmed, I., Adeghate, E., Sharma, A. K., Pallot, D. J. & Singh, J. (1998) Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Res. Clin. Pract. 40: 145-151.

Ahmed, I., Lakhani, M. S., Gillett, M., John, A. & Raza, H. (2001) Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 51: 155-161.

Ahmed, I., Adeghate, E., Cummings, E., Sharma, A. K. & Singh, J. (2004) Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol. Cell Biochem. 261: 63-70.

Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D. & Shah, S. T. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331: 1480-1487.

Alexandraki, K., Piperi, C., Kalofoutis, C., Singh, J., Alaveras, A. & Kalofoutis, A. (2006) Inflammatory process in type 2 diabetes: The role of cytokines. Ann. N. Y. Acad. Sci. 1084: 89-117.

Al-Zuabi, H., Al-Tammar, Y., Al-Moataz, R., Al-Sabti, K., Wani, V. B., Hamama, F., Mohammad, H. & Al-Suwayan, M. H. Retinopathy in newly diagnosed type 2 diabetes mellitus. : Med. Princ. Pract. 14: 293-296.

Anderson, J. W., Kendall, C. W. & Jenkins, D. J. (2003) Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J. Am. Coll. Nutr. 22: 331-339.

Aring, A. M., Jones, D. E. & Falko, J. M. (2005) Evaluation and prevention of diabetic neuropathy. Am. Fam. Physician. 71: 2123-2128.

Avellone, G., Garbo, V., Cordova, R., Rotolo, G., Abruzzese, G., Raneli, G., Simone, R. & Bompiani, G. D. (1994) Blood coagulation and fibrinolysis in obease NIDDM patients. Diabetes Res. 25: 85-92.

Ayodele, O. E., Alebiosu, C. O. & Salako, B. L. (2004) Diabetic nephropathy-a review of the natural history, burden, risk factors and treatment. J. Natl. Med. Assoc. 96: 1445-1454.

Baldwa, V. S., & Bhandari, C. M. (1977) Clinical trials in paitiens with diabetes mellitus on an insulin-like compound obtained from plant source. J. Med. Sci. 82: 39-41.

Bassi, A. M., Ledda, S., Penco, S., Menini, S., Muzio, G., Canuto, R. & Ferro, M. (2000) Changes of CYP1A1, GST and ALDH3 enzymes in hepatoma cell lines undergoing enhanced lipid peroxidation. Free. Radic. Biol. Med. 29: 1186-1196.

Basta, G., Lazzerini, G., Massaro, M., Simoncini, T., Tanganelli, P., Fu, C., Kislinger, T., Stern, D. M., Schmidt, A. M. & Caterina, R. (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 105: 816-822.

Basta, G., Schmidt, A. M. & Caterina, R. D. (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63: 582-592.

Bastard, J. P., Jardel, C., Bruckert, E., Blondy, P., Capeau, J., Laville, M., Vidal, H., & Hainque, B. (2000). Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrin. Metab. 85: 3338-3342.

Bath, P. M. & Butterworth, R. J. (1996) Platelet size: measurement, physiology and vascular disease. Blood Coagul. Fibrinolysis. 7: 157-161.

Bierhaus, A., Illmer, T., Kasper, M., Luther, T., Quehenberger, P., Tritschler, H., Wahl, P., Ziegler, R., Muller, M. & Nawroth, P. P. (1997) Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation. 96: 2262-2271.

Bjork, I. & Olson, J. E. (1997). Antithrombin, a bloody important serpin (in chemistry and biology of serpins). Plenum. Press. 17-33.

Blake, G. J. & Ridker, P. M. (2002) Inflammatory bio-markers and cardiovascular risk prediction. J. Intern. Med. 252: 283-294

Blann, A. D. & Taberner, D. A. (1995) A reliable marker of endothelial cell dysfunction: Does it exist ? Br. J. Haematol. 90: 244-248.

Block, G., Jensen, C., Dietrich, M., Norkus, E. P., Hudes, M. & Packer, L. (2004) Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. J. Am. Coll. Nutr. 23: 141-147.

Bonnefont-Rousselot, D. (2002) Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care 5: 561-568.

Browatzki, M., Schmidt, J., Kubler, W. & Kranzhofer, R. (2000) Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-κB in human vascular smooth muscle cells. Basic. Res. Cardiol. 95: 98-105.

Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.

Brownlee, M. (2003) A radical explanation for glucose-induced β-cell dysfunction. J. Clin. Invest. 112: 1788-1790.

Brownlee, M. (2005) The pathobiology of diabetic complications. Diabetes 54: 1615-1625.

Boeri, D., Almus, F. E., Maiello, M., Cagliero, E., Rao, L. V. & Lorenzi, M. (1989) Modification of tissue-factor mRNA and protein response to thrombin and interleukin 1 by high glucose in cultured human endothelial cells. Diabetes. 38: 212-218.

Bucala, R., Mitchell, R., Arnold, K., Innerarity, T., Vlassara, H. & Cerami, A. (1995) Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J. Biol. Chem. 270: 828-832.

Buse, M. G. (2006) Hexosamines, insulin resistance, and the complications of diabetes: current status. Am. J. Physiol. Endocrinol. Metab. 290: E1-E8.

Calles-Escandon, J., Garcia-Rubi, E., Mirza, S. & Mortensen, A. (1999) Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron. Artery. Dis. 10: 23-30.

Carr, M. E. (2001) Diabetes mellitus: a hypercoagulable state. J. Diabetes Complications 15: 44-54.

Carmassi F., Morale, M., Puccetti, R., De Negri, F., Monzani, F., Navalesi, R. & Mariani, G. (1992) Coagulation and fibrinolytic ststem impairement in insulin dependent diabetes mellitus. Thromb. Res. 67: 643-654.

Ceriello, A., Quatraro, A., Marchi, E., Barbanti, M., Dello-Russo, P., Lefebvre, P. & Giugliano, D. (1990) The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus. Diabet. Med. 7: 343-348.

Ceriello, A., Bortolotti, N., Pirisi, M., Crescentini, A., Tonutti, L., Motz, E., Russo, A., Giacomello, R., Stel, G. & Taboga, C. (1997) Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients. Diabetes Care 20: 1589-1593.

Ceriello, A. & Motz, E. (2004) Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? the common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. 24: 816-823.

Ceriello, A. (1993) Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 36: 1119-1125.

Cermak, J., Key, N. S., Bach, R. R., Balla, J., Jacob, H. S., Vercellotti, G. M. (1993) C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82: 513-520.

Chan, P. & Pan, W. H. (1995) Coagulation activation in type 2 diabetes mellitus: the higher coronary risk of female diabetic patients. Diabet. Med. 12: 504-507.

Chan, L. L., Chen, Q., Go, A. G., Lam, E.K. & Li, E. T. (2005) Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J. Nutr. 135: 2517-2523.

Chao, C. Y. & Huang, C. J. (2003) Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J. Biomed. Sci. 10: 782-91.

Chaturvedi, P., George, S., Milinganyo, M. & Tripathi, Y. B. (2004) Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats. Phytother. Res. 18: 954-956.

Chen, H., Ing, B. L., Robinson, K. A., Feagin, A. C., Buse, M. G. & Quon, M. J. (1997) Effects of overexpression of glutamine : fructose- 6- phosphate amidotransferase (GFAT) and glucosamine treatment on translocation of GLUT4 in rat adipose cells. Mol. Cell. Endocrinol. 135: 67-77.

Chen, Q., Chan, L. L. & Li, E. T. (2003) Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J. Nutr. 133: 1088-1093.

Charonis, A. S., Reger, L. A., Dege, J. E., Kouzi-Koliakos, K., Furcht, L. T., Wohlhueter, R. M. & Tsilibary, E. C. (1988) Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 39: 807-814.

Choi, H. J., Je, H. D., Jeong, J. H., Min, Y. S., Choi, T. S., Park, J. H., Shin, C. Y. & Sohn, U. D. (2003) The role of ascorbic acid on the redox status and the concentration of malondialdehyde in streptozotocin-induced diabetic rats. Arch. Pharm. Res. 26: 237-243.

Chung, S. S. M., Ho, E. C. M., Lam, K. S. L. & Chung, S. K. (2003) Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol. 14: S233-S236.

Chuang, C. Y., Hsu, C., Chao, C. Y., Wein, Y. S., Kuo, Y. H & Huang, C. J. (2006) Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARalpha in bitter gourd (Momordica charantia L.). J. Biomed. Sci. 13: 763-772.

Colwell, J. A. (1997) Multifactorial aspects of the treatment of the type II diabetic patient. Metabolism.46: 1-4.

Dandona, P., Aljada, A., Chaudhuri, A. & Bandyopadhyay, A. (2003) The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J. Clin. Endocrinol. Metab. 88: 2422-2429.

Deiezak, J. D. (1986) Preservatives: antioxidants-the ultimate answer to oxidation. Food Technol. 40: 34.

Dejanov, P., Polenakovic, M., Oncevski, A., Sikole, A., Dejanova, B., Panov, S. & Kostovska, S. (2004) The role of von Willebrand factor in renal diseases and haemodialysis patients. Prilozi. 25: 5-15.

Devaraj, S. & Jialal, I. (2000) Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic. Biol. Med. 29: 790-792.

Ding, Y., Vaziri, N. D., Coulson, R., Kamanna, V. S. & Roh, D. D. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am. J. Physiol. Endocrinol. Metab. 279: E11-E17.

Dominiczak, M. H. (2003) Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Clin. Chem. Lab. Med. 41: 1266-1287.

Drake, T. A., Hannani, K., Fei, H. H., Lavi, S. & Berliner, J. A. (1991) Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am. J. Pathol. 138: 601-607.

Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengeller, Z., Szabo, C. & Brownlee, M. (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 112: 1049-1057.

Du-Clos T. W. (2000) Function of C-reactive protein. Ann. Med. 32: 274-8.

Duman, B., S., Turkoglu, C., Gunay, D., Cagatay, P., Demiroglu, C. & Buyukdevrim, A. (2003) The interrelationship between insulin secretion and action in type 2 diabetes mellitus with different degrees of obesity: evidence supporting central obesity. Diabetes Nutr. Metab. 16: 243-250.

Dunn, E. J. & Grant, P. J. (2005) Type 2 diabetes: an atherothrombotic syndrome. Curr. Mol. Med. 5: 322-332.

Dutta, P. K., Chakravarty, A. K., Chowdhury, U. S. & Pakrashi, S. C. (1981) Vicine, a favism-inducing toxin from momordica charantia Linn seeds. Indian. J. Chem. 208: 669-671.

Economides, P. A., Khaodhiar, L., Caselli, A., Caballero, A. E., Keenan, H., Bursell, S. E., King, G. L., Johnstone, M. T., Horton, E. S. & Veves, A. (2005) The Effect of Vitamin E on Endothelial Function of Micro- and Macrocirculation and Left Ventricular Function in Type 1 and Type 2 Diabetic Patients. Diabetes 54: 204-211.

Elder, G. E., Mayne, E. E., Daly, J. G. Kennedy, A. L., Hadden, D. R. Montgomery, D. R. & Weaver, J. A. (1980) Antithrombin III activity and other coagulation changes in proliferative diabetic retinopathy. Haemostasis. 9: 288-296.

Erem, C., Hacihasanoglu, A., Celik, S., Ovali, E. Ersoz, H. O., Ukink, K., Deger, O. & Telatar, M. (2005) Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med. Princ. Pract. 14: 22-30.

Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A. & Giugliano, D. (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans role of oxidative stress. Circulation. 106: 2067-2072.

Esterbauer, H., Rotheneder, M., Waeg, G., Striedl, G., & Juergens, G. (1990) Biochemical, structural, and functional properties of oxidized low-density lipoproteins. Chem. Res. Toxicol. 3: 77-92.

Evans, J. L., Goldfine, I. D., Maddux, B. A. & Grodsky, G. M. (2003) Are oxidative stress-activated signaling pathways mediators en insulin resistance and β-cell dysfunction? Diabetes 52: 1-8.

Fabryova, L. & Cagan, S. (1998) Relation between insulin resistance and small, dense lipoproteins with low density and the development of atherosclerosis in type 2 diabetes mellitus. Bratisl. Lek. Listy. 99: 138-145.

Fu, M. X., Requena, J. R., Jenkins, A. J., Lyons, T. J., Baynes, J. W. & Thorpe, S. R. (1996) The advanced glycation end product, Nepsilon - (carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986.

Galajda, P., Martinka, E., Mokan, M. & Kubisz, P. (1997) Endothelial markers in diabetes mellitus. Thromb. Res. 85: 63-65.

Ghosh, K. (2002) Thrombohaemorrhagic balance in diabetes mellitus. J. Indian. Med. Assoc. 100: 428-430.

Giusti, C., Schiaffini, R., Brufani, C., Pantaleo, A., Vingolo, E. M. & Gargiulo, P. (2000) Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients. Br. J. Ophthalmol. 84: 591-595.

Goldberg, H. J., Scholey, J. & Fantus, I. G. (2000) Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cell. Diabetes. 49: 863-871.

Gosk-Bierska, I., Adamiec, R. Alexewicz, P. & Wysokinski, W. E. (2002) Coagulation in diabetic and non-diabetic claudicants. Int. Angiol. 21: 128-133.

Grattagliano, I., Vendemiale, G., Boscia, F., Micelli-Ferrari, T., Cardia, L. & Altomare, E. (1998) Oxidative retinal products and ocular damages in diabetic patients. Free Radic. Biol. Med. 25: 369-372.

Griselli, M., Herbert, J., Hutchinson, W. L., Taylor, K. M., Sohail, M. & Krausz, T. (1999) C-reactive protein and complement are imporent mediators of tissue damage in acute myocardial infarction. J. Exp. Med. 190: 1733-1740.

Gruden, G., Cavallo-Perin, P., Bazzan, M., Stella, S., Vuolo, A. & Pagano, G. (1994) PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 43: 426-429.

Guha, M., Bai, W., Nadler, J. L. & Natarajan, R. (2000) Molecular mechanisms of tumor necrosis factor α gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J. Biol. Chem. 275: 17728-17739.

Gurbuz, I., Akyuz, C., Yesilada, E. & Sener, B. (2000) Anti- ulcerogenic effect of Momordica charantia L. fruits on various ulcer models in rats. J. Ethnopharmacol. 71: 77-82.

Ha, H. & Lee, H. B. (2000) Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int. 58: S19-S25.

Haidara, M. A., Khloussy, H., Ammar, H. & Aal-Kassem, L. A. (2004) Impact of alpha-tocopherol and vitamin C on endothelial markers in rats with streptozotocin-induced diabetes. Med. Sci. Monit. 10: 41-46.

Haidara, H. A., Yassin, H. Z., Rateb, M., Ammar, H. & Zorkani, M. A. (2006) Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr. Vasc. Pharmacol. 4: 215-227.

Hall, P. K. & Roberts, R.C. (1989) Phosphate promotes glycation of antithrombin III which interferes with heparin binding. Biochim. Biophys. Acta. 993: 217-223.

Halliwell, B. & Gutteridge, J. M. C. (1998) The chemistry of free radicals and related reactive species. In “Free Redicals in Biology and Medicine.” B. Halliwell and J. M. C. Gutteridge, Eds., Clarendon Press, Oxford. Pp. 36-104.

Hammes, H. P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., Neumaier, M., Bergfeld, R., Giardino, I., & Brownlee, M. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9: 294-299.

Hazel, M., Cooksey, R. C., Jones, D., Parker, G., Neidigh, J. L., Witherbee, B., Gulve, E. A. & McClain, D. A. (2004) Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. Endocrinology 145: 2118-2128.

Henricsson, M., Nystrom, L., Blohme, G., Ostman, J., Kullberg, C., Svensson, M., Scholin, A., Arnqvist, H. J., Bjork, E., Bolinder, J., Eriksson, J. W. & Sundkvist, G. (2003) The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26: 349-354.

Hink, U., Li, H. & Mollnau, H. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res., 88: 14-22.

Hirano, T., Kashiwazaki, K., Moritomo, Y., Nagano, S. & Adachi, M. (1997) Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 36: 8-11.

Hjortoe, G. Sorensen, B. B., Petersen, L. C. & Rao, L. V. (2005) Factor VIIa binding and internalization in hepatocytes. J. Thromb. Haemost. 3: 2264-2273.

Hovens, M. M., Tamsma, J. T., Beishuizen, E. D. & Huisman, M. V. (2005) Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update. 65: 433-445

Huntington, J. A., Read, R. J. & Carrell, R. W. (2000). Structure of a serpin-protease complex shows inhibition by deformation. Nature 407: 923-926.

Iannello, S., Milazzo, P., Bordonaro, F. & Belfiore, F. (2005) Effect of in vitro glucose and diabetic hyperglycemia on mouse kidney protein synthesis: relevance to diabetic microangiopathy. MedGenMed. 7: 1.

Ibrahim, H. A., El-Meligi, A. A., Abdel-Hamid, M. & Elhendy, A. (2004) Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus. Med. Sci. Monit. 10: 85-89.

Idris, I., Gray, S. & Donnelly, R. (2001) Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia. 44: 659-673.

Igarashi, M., Wakasaki, H., Takahara, N., Ishii, H., Jiang, Z. Y., Yamauchi, T., Kuboki, K., Meier, M., Rhodes, C. J. & King, G. L. (1999) Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J. Clin. Invest. 103: 185-195.

Isomaa, B. (2003) A major health hazard: the metabolic syndrome. Life Sci. 73: 2395-2411.

Janero, D. R. (1990) Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med. 9: 515-540.

Jayasooriya, A. P., Sakono, M., Yukizaki, C., Kawano, M., Yamamoto, K. & Fukuda, N. (2000) Effects of momordica charantia power on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J. Ethnopharm. 72: 331-336.

Jerums, G. & MacIsaac, R. J. (2002) Treatment of microalbuminuria in patients with type 2 diabetes mellitus. Treat. Endocrinol. 1: 163-173.

Jiratchariyakul, W., Wiwat, C., Vongsakul, M., Somanabandhu, A., Leelamanit, W., Fujii, I., Suwannaroj, N. & Ebizuka, Y. (2001) HIV inhibitor from Thai bitter gourd. Planta. Med. 67: 350-353.

Johansen, O. E. & Birkeland, K. I. (2003) Preventing macrovascular disease in patients with type 2 diabetes mellitus. Am. J. Cardiovasc. Drugs. 3: 283-297.

Kadowaki, T., Hara K. & Yamauchi, T. (2003) Molecular mechanism of insulin resistance and obesity. Exp. Biol. Med. 228: 1111-11117.

Kang, E. S., Kim, H. J., Ahu, C. W., Park, C. W., Cha, B. S., Lim, S. K., Kim, K. R. & Lee, H. C. (2005) Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res. Clin. Park. 69: 151-159.

Kessler, L., Wiessel, M. L., Attali, P., Mossard, J. M., Cazenave, J. P. & Pingent, M. (1998) von Willebrand factor in diabetic angiopathy. Diabetes & Metabolism 24: 327-338.

Khanna, P. & Jain, S. C. (1981) Hypoglycemic activity of polypeptide-p from a plant source. J. Natural. Products. 44: 648-655.

Khechai, F., Ollivier, V., Bridey, F., Amear, M., Hakim, J. & Prost, D. (1997) Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes . Role of oxidant stress and protein tyrosine kinase activation. Arterioscler. Thromb. Vasc. Biol. 17: 2885-2890.

Kirpichnikov, D. & Sowers, J. R. (2001) Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol. Metab. 12: 225-230.

Klein, R. L., Laimins, M. & Lopes-Virella, M. F. (1995) Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of lowd-ensity lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 44: 1093-1098.

Knobl, P., Schernthanner, G., Schnack, C., Pietschmanns, P., Proidl, S., Prager, P. & Vukovich, T. (1994) Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb. Haemost. 71: 692-697.

Kolm-Litty, V., Sauer, U., Nerlich, A., Lehmann, R. & Schleicher, E. D. (1998) High glucose-induced transforming growth factor β1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101: 160-169.

Komosinska-Vassev, K., Olczyk, K., Olczyk, P. & Winsz-Szczotka, K. (2005) Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Res. Clin. Pract. 68: 207-216.

Koya, D. & King, G. L. (1997) Protein kinase C activation and the development of diabetic complications. Diabetes. 47: 859-866.

Kozek, E., Katra, B., Malecki, M. & Sieradzki, J. (2004) Visceral obesity and hemostatic profile in patients with type 2 diabetes: the effect of gender and metabolic compensation. Rev. Diabet. Stud. 1: 122-128.

Krawinkel, M. B. & Keding, G. B. (2006) Bitter gourd (momordica charantia): A dietary approach to hyperglycemia. Nutr. Rev. 64: 331-337.

Kumar-Shetty, A., Suresh-Kumar, G. & Veerayya-Salimath, P. (2005) Bitter gourd (Momordica charantia) modulates activities of intestinal and renal disaccharidases in streptozotocin-induced diabetic rats. Mol. Nutr. Food. Res. 49: 791-796.

Lapolla, A., Piarulli, F., Sartore, G., Ceriello, A., Ragazzi, E., Reitano, R., Baccarin, L., Laverda, B. & Fedele, D. (2007) Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30: 670-676.

Leiter, L. A. & Lewanczuk, R. Z. (2005) Of the renin-angiotensin system and reactive oxygen species. Am. J. Hypertens. 18: 121-128.

Leurs, P. B., Oerle, R., Wolffenbuttel, B. H. & Hamulyak, K. (1997) Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb. Haemost. 77: 472-476.

Li, L., Roumeliotis, N., Sawamura, T. & Renier, G. (2004) C-reactive protein enhances lox-1 expression in human aortic endothelial cells: relevance of lox-1 to C-reactive protein-induced endothelial dysfunction. Circ. Res. 95: 877-83.

Libby, P., Ridker, P. M. & Maseri, A. (2002) Inflammation and atherosclerosis. Circulation. 105: 1135– 43.

Lim, H. S., Chong, A. Y., Freestone, B., Blann, A. D. & Lip, G. Y. (2005) The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease. Diabet. Med. 22: 249-255.

Lip, G. Y. & Blann, A. (1997) von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc. Res. 34: 255-265.

Lotlikar, M. M. & Rajarama-Rao, M. R. (1962) Note on a hypoglycemic principle isolated from the fruits of momordica charantia. J. University Bombay. 29: 223-224.

Low, P. A., Benrud-Larson, L. M., Sletten, D. M., Opfer-Gehrking, T. L., Weigand, S. D., O''Brien, P. C., Suarez, G. A. & Dyck, P. J. (2004) Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 27: 2942-2947.

Lubas, W. A., Frank, D. W., Krause, M., & Hanover, J. A. (1997) O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J. Biol. Chem. 272: 9316-9324.

Majkowska, L., Mamos, E., Fuchs, H., Pynka, S., Jastrzebska, M., Krzyzanowska, B. & Czekalski, S. (1994) Selected parameters of blood coagulation and fibrinolysis and their relationship to the level of diabetes control in patients with insulin-dependent diabetes mellitus. Pol. Arch. Med. Wewn. 92: 147-153.

Manabe, M., Takenaka, R., Nakasa, T. & Okinaka, O. (2003) Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd). Biosci. Biotechnol. Biochem. 67: 2512-2517.

Mark, W. S. & Robert, J. C. (2003) Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin. Thera. 25: B4-B31.

Masato, K. (2006) Insulin resistance and pancreatic β cell failure. J. Clin. Invest. 116: 1756–1760.

McClain, D. A., Lubas, W. A., Cooksey, R. C., Hazel, M., Parker, G. J., Love, D. C. & Hanover, J. A. (2002) Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc. Natl. Acad. Sci. 99: 10695-10699.

Metcalf, P. A., Folsom, A. R., Davis, C. E. & Wu, K. K. (2000) Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus. Diabetes Res. Clin. Pract. 47: 25-35.

Miranda, M., Muriach, M., Roma, J., Bosch-Morell, F. Genoves, J. M., Barcia, J., Araiz, J., Diaz-Llospis, M. & Romero, F. J. (2006) Oxidative stress in a model of experimental diabetic retinopathy: the utility of peroxinytrite scavengers. Arch. Soc. Esp. Oftalmol. 81: 27-32.

Misawaa, S., Kuwabaraa, S., Ogawaraa, K., Kitanoa, Y., Yaguib, K. & Hattoria, T. (2004) Hyperglycemia alters refractory periods in human diabetic neuropathy. Clin. Neuro. 115: 2525-2529.

Miura, T., Itoh, Y., Iwamoto, N., Kato, M. & Ishida, T. (2004) Suppressive activity of the fruit of Momordica charantia with exercise on blood glucose in type 2 diabetic mice. Biol. Pharm. Bull. 27: 248-250.

Miyata, T., Horie, K., Ueda, Y., Fujita, Y., Izuhara, Y., Hirano, H., Uchida, K., Saito, A. & Kurokawa, K. (2000) Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int. 58: 425-35.

Mohora, M., Virgolici, B., Paveliu, F., Lixandru, D., Muscurel, C. & Greabu, M. (2006) Free radical activity in obese patients with type 2 diabetes mellitus. Rom. J. Intern. Med. 44: 69-78.

Morishita, E., Asakura, H., Jokaji, H., Saito, M., Uotani, C., Kumabashiri, I., Yamazaki, M., Aoshima, K., Hashimoto, T. & Matsuda, T. (1996) Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis. 120: 7-14.

Morrish, N. J., Wang, S. L., Stevens, L. K., Fuller, J. H. & Keen, H. (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44: S14-21.

Murakami, H., Okazaki, M., Amagasa, H. & Oguchi, K. (2003) Increase in hepatic mRNA expression of coagulant factors in type 2 diabetic model mice. Thromb. Res. 111: 81-87.

Napoleone, E., Di-Santo, A., Lorenzet, R. (1997) Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood. 89: 541-549.

Natarajan, R., Lanting, L., Gonzales, N. & Nadler J. (1996) Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am. J. Physiol. Heart. Circ. Physiol. 271: 159-165.

Neri, S., Signorelli, S. S., Torrisi, B., Pulvirenti, D., Mauceri, B., Abate, G., Ignaccolo, L., Bordonaro, F., Cilio, D., Calvagno, S. & Leotta, C. (2005) Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls. Clin. Ther. 27: 1764-1773.

Nerurkar, P. V., Pearson, L., Efird, J. T., Adeli, K., Theriault, A. G. & Nerurkar, V. R. (2005) Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J. Nutr. 135: 702-706.

Newton, A. C. (1995) Protein kinase C: structure, function and regulation; minireview. J. Biol. Chem. 270: 28495-28498.

Nishikawa, T., Edelstein, D. & Brownlee, M. (2000b) The missing link: a single unifying mechanism for diabetic complications. Kidney Int. 58: S26–S30.

Nomura, S., Imamura, A., Okuno, M., Kamiyama, Y., Fujimura, Y., Ikeda, Y. & Fukuhara, S. (2000). Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shearinduced microparticle generation by cytokines. Thrombosis Research 98: 257-268.

Novella, S. P., Inzucchi, S. E. & Goldstein, J. M. (2001) The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 24: 1229-1231.

Oates, P. J. (2002) The polyol pathway and diabetic peripheral neuropathy. Neur. Dia. Neur. 50: 325-392.

Obici, S. (2005) Hexosamine pathway contribution to insulin resistance- New insights from muscle specific GFAT transgenic. 65th Annu Mtg American Diabetes Association.

Obrosova, I. G., Fathallah, L. & Lang, H. J. (1999) Interaction between osmotic and oxidative stress in diabetic precataractous lens: studies with a sorbitol dehydrogenase inhibitor. Biochem. Pharmacol. 58: 1945-1954

Oers, C. A., Manschot, S. M., Huffelen, A. C., Kappelle, L. J. & Biessels, G. J. (2006) Cerebrovascular reserve capacity is preserved in a population-based sample of patients with type 2 diabetes mellitus. Cerebrovasc. Dis. 22: 46-50.

Olson, S. T. & Bjork, I. (1994). Regulation of thrombin activity by antithrombin and heparin. Sem. Thromb. Hemost. 20: 373-409.

Parham, P. (2000) The immune system. Garland Publishing/Elsevier Science, Ltd., pp.217-219.

Park, J. Y., Takahara, N., Gabriele, A., Chou, E., Naruse, K., Suzuma, K., Yamauchi, T., Ha, S. W., Meier, M., Rhodes, C. J. & King, G. L. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes. 49: 1239-1248.

Packer, L., Kraemer, K. & Rimbach, G. (2001) Molecular Aspects of Lipoic Acid in the Prevention of Diabetes Complications. Nutrition 17: 888-895.

Parving, H. H. & Hovind, P. (2002) Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr. Hypertens. Rep. 4: 387-393.

Patrassi, G. M., Vettor, R., Padovan, D. & Girolami, A. (1982) Contact phase of blood coagulation in diabetes mellitus. Eur. J. Clin. Invest. 12: 307-311.

Pearson, T. A., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, S. C., Taubert, K., Tracy, R. P. & Vinicor, F. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation. 107: 499-511.

Perry, D. J. (2002) Factor VII deficiency. Br. J. Haematol. 118: 689-700.

Pessin, J. E. & Saltiel, A. R. (2000) Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 106: 165–169.

Petitou, M., Duchaussoy, P., Herbert, J. M., Duc, G., Hajji, M., Branellec, J. F., Donat, F., Necciari, J., Cariou, R., Bouthier, J., & Garrigou, E. (2002) The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Thrombosis and Hemostasis 28: 393-402.

Pfutzner, A. & Forst, T. (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol. Ther. 8: 28-36.

Pickup, J. C. (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813-823.

Pinkney, J. H., Stehouwer, C. D., Coppack, S. W. & Yudkin, J. S (1997) Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 46: 9-13.

Pittas, A. G., Joseph, N. A. & Greenberg, A. S. (2004) Adipocytokines and insulin resistance. J. Clin. Endocrinol. Metab. 89: 447-452.

Pryor, W. A. (1994) Free radicals and lipid peroxidation: what they are and how they got the way. In “Nature Antioxidants in Human Health and Disease” Frei, B., Ed., Academic Press: San Diego, CA. pp. 1-24.

Quinsey, N. S., Greedy, A. L., Bottomley, S. P., Whisstock, J. C. & Pike, R. N. (2004) Antithrombin:in control of coagulation. Int. J. Biochem. Cell Biol. 36: 386-389.

Rathi, S. S., Grover, J. K., Vikrant, V. & Biswas, N. R. (2002) Prevention of experimental diabetic cataract by Indian Ayurvedic plant extracts. Phytother. Res. 16: 774-777.

Ridker, P. M. (2004) High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am. Heart J. 148: 19-26.

Ritz, E. (2006) Diabetic nephropathy. Saudi. J. Kidney Dis. Transpl. 17: 481-490.

Roffey, B. W., Atwal, A. S., Johns, T. & Kubow, S. (2007) Water extracts from momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J. Ethnopharmacol. 112: 77-84.

Ross R. (1999) Atherosclerosis an inflammatory disease. N. Engl. J. Med. 340: 115-126.

Rossing, P. (2006) Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr. Diab. Rep. 6: 479-483.

Ruggeri, Z. M., Ware, J. & Ginsberg, D. (1994) von Willebrand factor. 305-329.

Sadler, J. E. (1998) Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 67: 395-424.

Saltiel, A. R & Kahn, C. R. (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799–806.

Sarkar, S., Pranava, M. & Marita, R. (1996) Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol. Res. 33: 1-4.

Sathishsekar, D. & Subramanian, S. (2005) Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats. Biol. Pharm. Bull. 28: 978-983.

Schiekofer, S., Balletshofer, B. & Andrassy, M. (2000) Endothelial dysfunction in diabetes mellitus. Semin. Thromb. Hemost. 26: 503-511.

Schmidt, A. M. & Stern, D. (2002) Atherosclerosis and diabetes: the RAGE connection. Curr. Atheroscler. Rep. 2: 430-436.

Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F., Crandall, J., Zhang, J., Cao, R., Yan, S. D., Brett, J. & Stern, D. (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96: 1395-1403.

Schmitz-Peiffer, C. (2000) Signalling aspects of insulin resistance in skeletal muscle: mechanisms induced by lipid oversupply. Cellular Signal. 12: 583-594.

Sekar, D. S., Sivagnanam, K. & Subramanian, S. (2005) Antidiabetic activity of Momordica charantia seeds on streptozotocin induced diabetic rats. Pharmazie. 60: 383-387.

Seligman, B. G., Biolo, A., Polanczyk, C. A., Gross, J. L. & Clausell, N. (2000) Increased plasma levels of endothelin-1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 23: 1395-1400.

Senanayake, G. V., Maruyama, M., Shibuya, K., Sakono, M., Fukuda, N., Morishita, T., Yukizaki, C., Kawano, M. & Ohta, H. (2004) The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. J. Ethnopharmacol. 91: 257-262.

Shetty, A. K., Kumar, G. S., Sambaiah, K. & Salimth, P. V. (2005) Effect of bitter gourd (momordica charantia) on glycaemic status in streptozotocin induced diabetic rats. Plant Foods Hum. Nutr. 60: 109-112.

Shimoike, T., Inoguchi, T., Umeda, F., Nawata, H., Kawano, K. & Ochi, H. (2000) The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism. 49: 1030-1035.

Sims, T. J., Rasmussen, L. M., Oxlund, H. & Bailey, A. J. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia. 39: 946-951.

Singh, L. P., Green, K., Alexander, M., Bassly, S. & Crook, E. D. (2004) Hexosamines and TGF-β1 use similar signaling pathways to mediate matrix protein synthesis in mesangial cells. Am. J. Physiol. Renal. Physiol. 286: F409-F416.

Singleton, J. R., Smith, A. G. & Bromberg, M. B. (2001) Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 24: 1448-1453.

Sitasawad, S. L., Shewade, Y. & Bhonde, R. (2000) Role of bittergourd fruit juice in stz-induced diabetic state in vivo and in vitro. J. Ethnopharmacol 73: 71-79.

Slatter, D. A., Bolton, C. H. & Bailey, A. J. (2000) The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 43: 550-557.

Steffel, J., Hermann, M., Greutert, H., Gay, S., Luscher, T. F., Ruschitzka, F. & Tanner, F. C. (2005) Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation. 111: 1685-1689.

Steffel, J., Lüscher, T. F. & Tanner, F. C. (2006) Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 113: 722-731.

Suciu, I., Negrean, V. & Sampelean, D. (2004) The oxidative stress in the development of diabetes chronic complications in the elderly. Rom. J. Intern. Med. 42: 395-406.

Tajunisah, I., Nabilah, H. & Reddy, S. C. (2006) Prevalence and risk factors for diabetic retinopathy-a study of 217 patients from University of Malaya Medical Centre. Med. J. Malaysia. 61: 451-456.

Takamiya, O., Seta, M. Tanaka, K. & Ishida, F. (2002) Human factor VII deficiency caused by S339C mutation located adjacent to the specificity pocket of the catalytic domain. Clin. Lab. Haematol. 24: 233-238.

Takeuchi, M., Yanase, Y., Matsuura, N., Yamagishi, S. S., Kameda, Y., Bucala, R. & Makita, Z. (2001) Immunological detection of a novel advanced glycation end-product. Mol. Med. 7: 783-791.

Talu, S., Kaucsar, E. & Soreanu, A. (2002) Diabetic retinopathy in newly diagnosed patients with type II diabetes mellitus. Oftalmologia. 54: 27-30.

Tan, K. C., Chow, W. S., Tam, S., Bucala, R. & Betteridge, J. (2004) Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care. 27: 223-228.

Thompson, D., Harrison, S. P., Evans, S. W. & Whicher, J. T. (1991) Insulin modulation of acute phase protein production in a human hepatoma cell line. Cytokine 3: 619-626.

Thornalley, P. J., Langborg, A. & Minhas, H. S. (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344: 106-16.

Tillet, W. S. & Francis, J. T. (1930) Serological reaction in pneumonia with a nonprotein somatic fraction of pneumococcus. J. Exp. Med. 52: 561-585.

Tkac, I., Troscak, M., Javorsky, M., Petrik, R. & Tomcova, M. (2001) Increased intracranial arterial resistance in patients with type 2 diabetes mellitus. Wien. Klin. Wochenschr. 113: 870-873.

Torzewski, M., Rist, C. & Mortensen, R. F. (2000) C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20: 2094-2099.

Tousoulis, D., Antoniades, C., Tountas, C., Bosinakou, E., Kotsopoulou, M., Toutouzas, P. & Stefanadis, C. (2003) Vitamin C affects thrombosis/ fibrinolysis system and reactive hyperemia in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 26: 2749-2753.

Tschoepe, D., Roesen, P., Schwipper, B. & Gries, F. A. (1993) Platelets in diabete: the role in the hemostatic regulation in atherosclerosis. Semin. Thromb. Hemost. 19: 122-128.

Tuttle, H. A., Davis-Gorman, G., Goldman, S., Copeland, J. G. & McDonagh, P. F. (2004) Proinflammatory cytokines are increased in type 2 diabetic women with cardiovascular disease. J. Diabetes Complications. 18: 343-351.

Vericel, E., Januel, C., Carreras, M., Moulin, P. & Lagarde, M. (2004) Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 53: 1046-51.

Verma, S., Li, S. H., Badiwala, M. V., Weisel, R. D., Fedak, P. W., Li, R. K., Dhillon, B. & Mickle, D. A. (2002) Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 105: 1890-1896.

Villanueva, G. B. & Allen, N. (1988) Demonstration of altered antithrombin III activity due to nonenzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients. Diabetes. 37: 1103-1107.

Vinik, A. & Flemmer, M. (2002) Diabetes and macrovascular disease. J. Diabetes Complications 16: 235-245.

Vinik, A. I., Erbas, T., Park, T. S., Nolan, R. & Pittenger, G. L. (2001) Platelet dysfunction in type 2 diabetes. Diabetes Care 24: 1476-1485.

Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A. & Pasagian, A. (1998) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240: 1546-1548.

Wada, H., Kaneko, T., Wakita, Y., Minamikawa, K., Nagaya, S., Tamaki, S., Deguchi, K. & Shirakawa, S. (1994) Effect of lipoproteins on tissue factor activity and PAI-II antigen in human monocytes and macrophages. Int. J. Cardiol. 47: 21-25.

Wagner, D. D. (1990) Cell biology of von Willebrand factor. Annu. Rev. Cell. Biol. 6: 217-246.

Wakasaki, H., Koya, D., Schoen, F. J., Jirousek, M, R., Ways, D. K., Hoit, B. D., Walsh, R. A. & King, G. L. (1997) Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. 94: 9320-9325.

Way, K. J. & Katai, N. & King, G. L. (2001) Protein kinase C and the development of diabetic vascular complications. Diabetes. 18: 945-959.

Wellen, K. E. & Hotamisligil, G. S. (2003) Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112: 1785-1788.

Wildgoose, P., Nemerson, Y., Hansen, L.L., Nielsen, F.E., Glazer, S. & Hedner, U. (1992) Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 80: 25-28.

Willa, A., Hsueh, M. D. & Ronald, L. (2003) The central role of fat and effect of peroxisome proliferator-pctivated receptor–γ on progression of insulin resistance and cardiovascular disease. Am. J. Cardiol. 92: 3J–9J.

Wilson, A. M., Ryan, M. C. & Boyle, A. J. (2006) The novel role of C-reactive protein in cardiovascular disease: Risk marker or pathogen. Int. J. Cardiol. 106: 291-297.

Xu, X., Chen, P., Wu, X., Feng, X., Wang, Q. & Zhang, L. (2001) Renal protective effects of vitamin E in diabetic rats. Zhonghua. Nei. Ke. Za. Zhi. 40(5): 321-324.

Yamagishi S. I., Edelstein, D., Du, X. L., Kaneda, Y., Guzman, M. & Brownlee, M. (2001) Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J. Biol. Chem. 276: 25096-25100.

Yamakawa, T., Eguchi, S., Matsumoto, T., Yamakawa, Y., Numaguchi, K., Miyata, I., Reynolds, C. M., Motley, E. D. & Inagami, T. (1999) Intracellular signaling in rat cultured vascular smooth muscle cells: roles of nuclear factor-kappaB and p38 mitogen-activated protein kinase on tumor necrosis factor-alpha production. Endocrinology. 140: 3562-3572.

Yki-Jarvinen, H. (2000) Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs. 60: 975-983.

Young, I. S. Torney, J. J. & Trimble, E. R. (1992) The effect of ascorbate supplementation on oxidative stress in the streptozotocin diabetic rat. Free Radic. Biol. Med. 13: 41-46.

Ziegler, D., Sohr, C. G. H. & Nourooz-Zadeh, J. (2004) Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care. 27: 2178-2183.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top